Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADVMNASDAQ:ATRANASDAQ:KRYSNASDAQ:MGTXNASDAQ:VCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$9.39-7.9%$15.62$7.10▼$29.70$211.49M0.84191,930 shs838,744 shsATRAAtara Biotherapeutics$0.70-1.4%$0.72$0.20▼$3.02$85.31M0.691.04 million shs865,826 shsKRYSKrystal Biotech$155.68-2.1%$163.46$82.09▼$189.97$4.54B0.85253,618 shs242,413 shsMGTXMeiraGTx$4.71-3.1%$5.85$3.49▼$8.35$312.10M1.29150,163 shs121,649 shsVCELVericel$45.45-1.4%$47.44$29.70▼$53.05$2.23B1.71340,198 shs258,209 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-7.85%-15.78%-33.64%-0.05%+17.13%ATRAAtara Biotherapeutics-2.08%+1.17%+5.87%+16.19%-74.37%KRYSKrystal Biotech-2.12%-5.06%-10.62%+34.17%+82.04%MGTXMeiraGTx-3.09%-5.99%-23.54%-30.22%-12.45%VCELVericel-1.43%+3.63%-8.29%+6.69%+48.72%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies3.7876 of 5 stars3.51.00.04.82.42.50.0ATRAAtara Biotherapeutics3.7569 of 5 stars3.01.00.04.72.62.50.6KRYSKrystal Biotech4.0994 of 5 stars2.51.00.04.72.73.31.9MGTXMeiraGTx4.2454 of 5 stars3.53.00.04.82.51.70.6VCELVericel0.5036 of 5 stars1.50.00.00.02.70.81.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies3.00Buy$34.67269.19% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,901.14% UpsideKRYSKrystal Biotech3.00Buy$171.009.84% UpsideMGTXMeiraGTx3.00Buy$25.67444.94% UpsideVCELVericel3.00Buy$46.402.09% UpsideCurrent Analyst RatingsLatest ATRA, KRYS, ADVM, VCEL, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$200.004/16/2024KRYSKrystal BiotechStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$178.00 ➝ $204.003/26/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/1/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.003/1/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$46.00 ➝ $53.002/27/2024KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $175.002/27/2024KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$160.00 ➝ $195.002/27/2024KRYSKrystal BiotechWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$3.60M54.12N/AN/A$8.26 per share1.14ATRAAtara Biotherapeutics$8.57M9.75N/AN/A($0.97) per share-0.72KRYSKrystal Biotech$50.70M87.54N/AN/A$27.60 per share5.64MGTXMeiraGTx$14.02M21.57N/AN/A$2.17 per share2.17VCELVericel$197.52M11.13$0.02 per share2,616.62$4.73 per share9.61Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)KRYSKrystal Biotech$10.93M$0.081,946.2439.31N/AN/A-13.31%-12.61%5/13/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.23N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)VCELVericel-$3.18M-$0.09N/A90.90N/A-1.61%-1.55%-1.02%5/8/2024 (Confirmed)Latest ATRA, KRYS, ADVM, VCEL, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/AVCELVericel-$0.11N/A+$0.11N/AN/AN/A 3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million2/29/2024Q4 2023VCELVericel$0.18$0.26+$0.08$0.26$64.28 million$65.00 million 2/26/202412/31/2023KRYSKrystal Biotech-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A4.134.13ATRAAtara BiotherapeuticsN/A0.720.65KRYSKrystal BiotechN/A17.7617.55MGTXMeiraGTx0.622.382.38VCELVericelN/A4.494.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ATRAAtara Biotherapeutics70.90%KRYSKrystal Biotech86.29%MGTXMeiraGTx67.48%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies5.30%ATRAAtara Biotherapeutics4.50%KRYSKrystal Biotech14.10%MGTXMeiraGTx9.70%VCELVericel5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies12120.75 million19.66 millionOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableKRYSKrystal Biotech22928.51 million24.49 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableVCELVericel31448.38 million45.86 millionOptionableATRA, KRYS, ADVM, VCEL, and MGTX HeadlinesSourceHeadlineHere's Why Shareholders May Want To Be Cautious With Increasing Vericel Corporation's (NASDAQ:VCEL) CEO Pay Packetfinance.yahoo.com - April 26 at 8:48 AMNew York State Common Retirement Fund Sells 30,717 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 25 at 8:29 AMVericel to Report First-Quarter 2024 Financial Results on May 8, 2024globenewswire.com - April 24 at 8:30 AMFederated Hermes Inc. Has $19.96 Million Stock Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 22 at 5:56 AMVericel Corporation (VCEL) stock historical prices & data – Yahoo Financenz.finance.yahoo.com - April 21 at 11:52 PMDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stockinsidertrades.com - April 21 at 4:32 AMVericel Co. (NASDAQ:VCEL) CEO Sells $780,325.00 in Stockinsidertrades.com - April 20 at 7:12 AMVericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Sharesmarketbeat.com - April 19 at 6:44 PMKnights of Columbus Asset Advisors LLC Purchases 112,169 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 19 at 1:38 PMVericel Corpmoney.usnews.com - April 17 at 9:10 PMMutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 15 at 5:51 AMVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Evenfinance.yahoo.com - April 13 at 1:24 PMVericel Co. (NASDAQ:VCEL) Sees Large Increase in Short Interestmarketbeat.com - April 12 at 10:31 AMVericel Co. (NASDAQ:VCEL) Shares Acquired by Conestoga Capital Advisors LLCmarketbeat.com - April 10 at 3:55 PMVericel Co. (NASDAQ:VCEL) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - April 8 at 4:13 AMCommit To Buy Vericel At $25, Earn 9% Annualized Using Optionsnasdaq.com - April 7 at 10:47 PMVericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Sharesinsidertrades.com - March 30 at 7:35 AMVericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLCmarketbeat.com - March 30 at 4:17 AMVericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40marketbeat.com - March 27 at 11:23 AMAnalyst Scoreboard: 5 Ratings For Vericelmarkets.businessinsider.com - March 27 at 1:54 AMTruist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)marketbeat.com - March 26 at 9:35 AMVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stockinsidertrades.com - March 14 at 9:39 AMVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stockinsidertrades.com - March 12 at 4:46 AMVCEL Oct 2024 50.000 callca.finance.yahoo.com - March 3 at 7:05 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Krystal BiotechNASDAQ:KRYSKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.VericelNASDAQ:VCELVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.